Merck pairs PD-1 powerhouse Keytruda with Genexine vax to fight HPV-based cancers

Research
Merck on Wednesday partnered with Genexine to test its Keytruda in conjunction with the biotech's cancer vaccine, GX-188E.

Years after two late-stage cancer vaccine failures put the field’s future in question, leading companies still believe they can amp up combo regimens. Now, Merck is partnering its key immunotherapy Keytruda with a Genexine vax to battle cervical cancer.

Merck will test its cancer-fighting checkpoint inhibitor Keytruda in combo with the biotech’s cancer vaccine, GX-188E, in HPV-induced cancers. They’ll start with a Phase Ib/IIa trial, with an option to expand the collaboration into Phase III registration studies in the indication.

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

It's the latest team-up between a checkpoint inhibitor and a cancer vaccine as Big Pharma puts its R&D machine behind the approach. South Korea-based Genexine in a statement said it believes Keytruda can complement its vaccine to improve on the 12.5% response rate the Merck drug posted alone in advanced cervical squamous cell cancer.

The pair will start the trial in the first half of 2017 in up to 40 patients. Genexine is currently developing its vaccine in Phase II trials in cervical intraepithelial neoplasia and in Phase I for HPV cancers.

The partnership joins a stream of collaborations after late-stage cancer vax failures by Merck KGaA and GlaxoSmithKline left a cloud on the field. Looking for a path forward in 2014, Johan Vansteenkiste of Belgium University Hospitals Leuven said that such combos could be of “major interest.”

Those words continue to ring true as leading biopharmas including Bristol-Myers Squibb and AstraZeneca have partnered their checkpoint inhibitors with cancer vaccines from smaller biotechs Bavarian Nordic and Inovio, respectively. For the biotechs, success could mean big payoffs approaching $1 billion.

Johnson & Johnson, for its part, has partnered with GVAX developer Aduro in a collaboration potentially worth $817 million.

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

Roche and Blueprint's RET inhibitor Gavreto has won FDA go-ahead to treat certain types of thyroid cancer, leveling the field with Lilly's Retevmo.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.